Neurological Biomarkers Market Updates

Neurological Biomarkers Market size was valued at USD 6.96 Billion in 2023 and is poised to grow from USD 7.91 Billion in 2024 to USD 21.94 Billion by 2032, growing at a CAGR of 13.6% during the forecast period (2025-2032).

Key vendors in Neurological Biomarkers Market are: 'Quanterix Corporation ', 'Thermo Fisher Scientific Inc. ', 'Myriad Genetics, Inc. ', 'QIAGEN N.V.', 'Bio-Rad Laboratories, Inc. ', 'Merck KGaA ', 'F. Hoffmann-La Roche Ltd ', 'Bio-Techne Corporation ', 'Alector Inc. ', 'Banyan Biomarkers, Inc. ', 'Charles River Laboratories International, Inc. ', 'Cisbio ', 'C2N Diagnostics ', 'ImmunArray ', 'Euroimmun AG ', 'Cerebrospinal Fluid Diagnostics ', 'Abbott Laboratories'

As biomarkers are important indicators of various health or disease traits. Cancer goes through a multistage carcinogenesis procedure involving multiple events from various molecular pathways, which makes its diagnosis, prognosis and therapy extremely complicated. Due to this complexity, a single marker is insufficient. In addition, each cancer type has its unique molecular profile. Identification of new biomarkers leads to the development of targeted therapies that target dysregulation in cancer. The increasing prevalence of cancer will, in turn, stimulate biomarker research and thereby boosting the growth of neurological biomarkers market. 

Increasing Funds for Research: The rising presence of companies offering funds at several stages of research is boosting market growth. For example, the University of North Texas Health Science Center (HSC) was offered almost USD 45.5 million in funds from the National Institutes of Health (NIH). This fund will help in supporting research related to health disparities in Alzheimer's and brain aging. NIH is also offering additional funds for biomarkers research for the present study for Health and Aging Brain Among Latino Elders (HABLE). Therefore, this new trend is fueling market growth. 

The largest piece in the global neurological biomarkers market share is held by North America. This growth is mainly due to the well-established healthcare and research infrastructure in the region. The United States and Canada houses major pharmaceutical and biotechnology companies which provides them a competitive advantage in the research & development for new neurological biomarkers. Moreover, the renowned medical device players involved in neurobiology are also contributing to the regional growth market. The market growth is also supported by the initiatives from government bodies providing grants and funding for different neuroscience projects. Various U.S. and Canadian universities and academic institutions are collaborating with industry to develop new biomarkers.